Clovis Oncology, Inc. - Common Stock (NQ:CLVS)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 20, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Clovis Oncology, Inc. - Common Stock

< Previous 1 2 Next >

Analysts Holding As Pfizer Waits On Two Phase 3 Studies

February 24, 2023

Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.

Via MarketBeat

Topics Bankruptcy

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

December 12, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat

October 27, 2022

From Clovis

Via Business Wire

Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies

November 07, 2022

Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and...

Via FinancialNewsMedia

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

October 17, 2022

From Clovis

Via Business Wire

TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations

October 03, 2022

From Clovis

Via Business Wire

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

September 21, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

September 11, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

August 08, 2022

From Clovis Oncology, Inc.

Via Business Wire

CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

July 20, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status

June 06, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting

June 14, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference

May 05, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

May 04, 2022

From Clovis Oncology, Inc.

Via Business Wire

HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for Patients

May 04, 2022

Palm Beach, FL – May 4, 2022 – FinancialNewsMedia.com News Commentary – Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over the last several years...

Via FinancialNewsMedia

Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting

April 28, 2022

From Clovis Oncology, Inc.

Via Business Wire

Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating

April 25, 2022

Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer...

Via FinancialNewsMedia

Topics Intellectual Property

Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4

April 20, 2022

From Clovis Oncology, Inc.

Via Business Wire

Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing

April 14, 2022

Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically...

Via FinancialNewsMedia

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

April 08, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial

March 31, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286

March 16, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting

February 25, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones

February 23, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call

February 10, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021

January 10, 2022

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit

December 09, 2021

From Clovis Oncology, Inc.

Via Business Wire

Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027

November 03, 2021

Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast,...

Via FinancialNewsMedia

Clovis Oncology Announces Third Quarter 2021 Operating Results

November 03, 2021

From Clovis Oncology, Inc.

Via Business Wire

Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3

October 20, 2021

From Clovis Oncology, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.